Comparative Pharmacology
Head-to-head clinical analysis: EVOCLIN versus STATICIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVOCLIN versus STATICIN.
EVOCLIN vs STATICIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, blocking peptide bond formation.
STATICIN is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
EVOCLIN (clindamycin phosphate) foam 1%: Apply once daily to affected area(s) of the face, shoulders, chest, and back.
500 mg orally every 12 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 15 hours (range 10-25 hours) following topical application, allowing for twice-daily dosing.
6-8 hours in adults with normal renal function; extends to 12-20 hours in moderate renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for approximately 10% of elimination. Biliary/fecal excretion accounts for <2%.
Renal excretion of unchanged drug accounts for 70-80% of total clearance; biliary/fecal excretion accounts for 15-20%; <5% metabolized.
Category C
Category C
Topical Antibiotic
Topical Antibiotic